Recombinant Salmonella Vaccination Technology and Its Application to Human Bacterial Pathogens

Author(s): Song Zhang, Nancy Walters, Ling Cao, Amanda Robison, Xinghong Yang

Journal Name: Current Pharmaceutical Biotechnology

Volume 14 , Issue 2 , 2013


Become EABM
Become Reviewer
Call for Editor

Abstract:

Salmonella enterica is a Gram-negative intracellular bacterial pathogen which causes salmonellosis in humans and animals. During the past several decades, extensive studies have shown that the attenuated Salmonella vaccine vector is an optimal vehicle for delivering passenger antigens to mucosal sites to induce humoral, cellular, and mucosal immunity. This immunity leads to protection against challenges with the wild-type pathogens from which the passenger antigens were derived. A myriad of studies have demonstrated that using attenuated Salmonella vaccines for recombinant multivalent vaccine construction has multiple advantages. In this review, we summarize these advantages and further evaluate the Salmonella-based vaccines against five bacterial diseases. Four of these are Gram-negative pathogens— Escherichia coli, Helicobacter pylori, Shigella dysenteriae, and Yersinia pestis—and one is a mycobacterial pathogen, Mycobacterium tuberculosis. Apart from H. pylori, the Salmonella-based vaccines against the other four pathogens exhibit excellent performance in safety, immunogenicity, and protection. These properties qualify them to be as a new generation of vaccines for preventing infections from bacterial pathogens.

Keywords: Escherichia coli, Helicobacter pylori, Mycobacterium tuberculosis, passenger antigen, recombinant vaccine, Salmonella vaccine vector, Shigella dysenteriae, Yersinia pestis

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 2
Year: 2013
Page: [209 - 219]
Pages: 11
DOI: 10.2174/1389201011314020011
Price: $65

Article Metrics

PDF: 12